Indian drugmaker Dr Reddy's posts quarterly profit slump
22/07/2026 11:51
Indian drugmaker Dr Reddy's posts quarterly profit slump HYDERABAD, July 22 (Reuters) - Indian drugmaker Dr Reddy's REDY.NS reported a smaller-than-expected quarterly profit on Wednesday, as muted sales of a key generic oncology drug and pricing pressure weighed on the competitive U.S. market.
Consolidated net profit tanked 68.7% to 4.44 billion rupees ($45.98 million) in the first quarter ending June 30.
Analysts, on average, had estimated profit to fall to 7.22 billion rupees, according to data compiled by LSEG.
($1 = 96.5650 Indian rupees)
(Reporting by Rishika Sadam and Kashish Tandon)
Recent news on Dr. Reddy's Laboratories
See all newsDr Reddy's rolls out new generic Ozempic brands to ease Obeda supply hit
Dr Reddy's beats quarterly profit estimate on India market lift (updated)
India's Dr Reddy's beats quarterly profit estimate
Brief: Dr. Reddy's Q2 Consol Net PAT 9.25 Billion Rupees
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption